Immune checkpoint inhibitors targeting PD-1 and PD-L1 have become the backbone of systemic therapy across non-small cell lung cancer, melanoma, urothelial carcinoma, renal cell carcinoma, head and neck squamous cell carcinoma, and many other solid tumors. The global market is valued at approximately $68 billion in 2026 and is projected to exceed $150 billion by the mid-2030s. Seven branded checkpoint inhibitors are currently marketed in the US, and the introduction of subcutaneous formulations is reshaping how these drugs are administered, billed, and covered.
This landscape covers the access picture across all approved PD-1 and PD-L1 inhibitors — including formulary positioning, payer step therapy, Medicare Part B reimbursement, HCPCS coding, the subcutaneous transition, IRA Part B negotiation, and the biosimilar horizon.
Who this is for
Market access teams, oncology practice managers, billing and coding staff, and payer-facing professionals who need a source-cited overview of how checkpoint inhibitor coverage differs by product, formulation, and payer in 2026.
Approved products at a glance
| Drug | Generic | Target | Manufacturer | Route | WAC per dose (approx.) | Dosing |
|---|---|---|---|---|---|---|
| Keytruda | Pembrolizumab | PD-1 | Merck | IV | ~$12,194 (200 mg) | Q3W or Q6W |
| Keytruda Qlex | Pembrolizumab + berahyaluronidase | PD-1 | Merck | SC | ~$16,625 | Q6W |
| Opdivo | Nivolumab | PD-1 | BMS | IV | ~$8,510 (240 mg) | Q2W, Q4W, or Q6W |
| Opdivo Qvantig | Nivolumab + hyaluronidase | PD-1 | BMS | SC | ~$12,950 | Q4W |
| Libtayo | Cemiplimab | PD-1 | Regeneron/Sanofi | IV | ~$7,350 (350 mg) | Q3W |
| Jemperli | Dostarlimab | PD-1 | GSK | IV | ~$7,125 (500 mg) | Q3W then Q6W |
| Tecentriq | Atezolizumab | PD-L1 | Genentech/Roche | IV | ~$9,950 (840 mg) | Q2W, Q3W, or Q4W |
| Tecentriq Hybreza | Atezolizumab + hyaluronidase | PD-L1 | Genentech/Roche | SC | ~$13,800 | Q3W |
| Imfinzi | Durvalumab | PD-L1 | AstraZeneca | IV | ~$9,100 (10 mg/kg) | Q2W or Q4W |
| Bavencio | Avelumab | PD-L1 | EMD Serono/Pfizer | IV | ~$6,250 (10 mg/kg) | Q2W |
| Opdualag | Nivolumab + relatlimab | PD-1 + LAG-3 | BMS | IV | ~$17,000 | Q4W |
Additional products with narrower labels include Loqtorzi (toripalimab, nasopharyngeal carcinoma), Tevimbra (tislelizumab, esophageal squamous cell carcinoma), Unloxcyt (cosibelimab, cutaneous squamous cell carcinoma), and Zynyz (retifanlimab, Merkel cell carcinoma).
Subcutaneous formulations: the IV-to-SC transition
Three checkpoint inhibitors now have FDA-approved subcutaneous (SC) formulations:
Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph): Approved September 2025. SC injection administered over approximately 2 minutes every 6 weeks (or 1 minute every 3 weeks). FDA-approved for all Keytruda indications except classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. HCPCS code J9277 effective April 1, 2026.
Opdivo Qvantig (nivolumab + hyaluronidase-nvhy): Approved December 2024. SC injection administered over approximately 3–5 minutes every 4 weeks. Covers most Opdivo monotherapy indications. HCPCS code J9289.
Tecentriq Hybreza (atezolizumab + hyaluronidase-tqjs): Approved September 2024. SC injection administered over approximately 7 minutes every 3 weeks. Covers all Tecentriq indications. HCPCS code J9024.
Access implications of the SC transition
The shift from IV to SC changes three access variables:
Administration setting. SC administration can potentially move patients out of infusion centers into clinic offices, reducing chair time and nursing resources. This is especially significant for high-volume oncology practices.
Reimbursement methodology. IV checkpoint inhibitors billed under Medicare Part B are reimbursed at ASP + 6% as buy-and-bill products. SC formulations billed under the same Part B mechanism may carry a different per-dose WAC and ASP, creating margin differences for practices.
Payer step therapy. UnitedHealthcare's Medicare Advantage step therapy program for 2026 positions Keytruda Qlex as preferred (alongside IV Keytruda, Libtayo, and Tecentriq/Tecentriq Hybreza) in NSCLC monotherapy for PD-L1 ≥ 50%. Aetna's Medicare Part B step therapy program similarly lists Keytruda Qlex as a non-preferred product requiring step therapy through preferred agents.
J-code timing. Keytruda Qlex received its dedicated J-code (J9277) effective April 1, 2026. Until a permanent J-code is in place, interim billing with J3590 or J9999 creates claim processing friction.
Payer step therapy and preferred products
Major payers are differentiating between checkpoint inhibitors through step therapy and preferred/non-preferred tiering:
UnitedHealthcare Medicare Advantage (effective May 2026)
For NSCLC monotherapy when PD-L1 expression is ≥ 50%:
| Preferred | Non-preferred (step therapy required) |
|---|---|
| Keytruda (IV) | Opdivo + Yervoy |
| Keytruda Qlex (SC) | |
| Libtayo | |
| Tecentriq (IV) | |
| Tecentriq Hybreza (SC) |
Non-preferred products require documentation of prior use, intolerance, or adverse events with preferred products.
Aetna Medicare (effective March 2026)
For NSCLC monotherapy:
| Preferred | Non-preferred (targeted) |
|---|---|
| Libtayo | Imfinzi |
| Keytruda | |
| Keytruda Qlex | |
| Opdivo | |
| Opdivo Qvantig | |
| Tecentriq | |
| Tecentriq Hybreza |
Aetna's positioning of Libtayo as the sole preferred agent is notable and creates a direct access hurdle for the market-leading Keytruda.
Commercial payers
Commercial payer policies are generally less restrictive than Medicare Advantage step therapy programs. Most commercial payers cover all checkpoint inhibitors when used for FDA-approved indications, with prior authorization focused on confirming diagnosis, biomarker status, and prior therapy history. Coverage for off-label use typically requires NCCN Category 1 or 2A support.
HCPCS codes for billing
| Product | HCPCS Code | Description |
|---|---|---|
| Keytruda (IV) | J9271 | Pembrolizumab, 1 mg |
| Keytruda Qlex (SC) | J9277 | Pembrolizumab + berahyaluronidase, 1 mg (eff. 04/01/26) |
| Opdivo (IV) | J9299 | Nivolumab, 1 mg |
| Opdivo Qvantig (SC) | J9289 | Nivolumab + hyaluronidase |
| Opdualag | J9298 | Nivolumab + relatlimab, 3 mg/1 mg |
| Libtayo | J9119 | Cemiplimab, 1 mg |
| Jemperli | J9272 | Dostarlimab, 10 mg |
| Tecentriq (IV) | J9022 | Atezolizumab, 10 mg |
| Tecentriq Hybreza (SC) | J9024 | Atezolizumab + hyaluronidase, 5 mg |
| Imfinzi | J9173 | Durvalumab, 10 mg |
| Bavencio | J9023 | Avelumab, 10 mg |
| Loqtorzi | J3263 | Toripalimab, 1 mg |
| Tevimbra | J9329 | Tislelizumab, 1 mg |
| Zynyz | J9345 | Retifanlimab, 1 mg |
| Unloxcyt | J9275 | Cosibelimab, 2 mg |
| Yervoy | J9228 | Ipilimumab, 1 mg |
IRA Part B negotiation: Keytruda and Opdivo in 2028
The Inflation Reduction Act (IRA) authorizes Medicare to negotiate prices for Part B drugs beginning with the third cycle (prices effective 2028). Keytruda (pembrolizumab) and Opdivo (nivolumab) are projected to be the only two Part B drugs selected for this cycle, because most other high-spend Part B drugs will face biosimilar or generic competition by then.
For access teams, this means:
- Negotiated maximum fair prices (MFP) for Keytruda and Opdivo will take effect no earlier than 2028. The exact MFP will be published after the negotiation process concludes.
- The MFP applies only to Medicare Part B dispensing, not commercial or Medicaid. However, commercial payers often reference Medicare rates in their own contracting.
- Biosimilar competition may arrive first. Multiple pembrolizumab biosimilars are in late-stage development. If biosimilars launch before or alongside MFP implementation, ASP erosion could outpace the negotiated price.
Biosimilar horizon
Keytruda and Opdivo are among the most significant biosimilar targets in oncology:
- Pembrolizumab biosimilars: Multiple companies including Sandoz, Biocon, Samsung Bioepis, Celltrion, and others are advancing pembrolizumab biosimilar programs. First launches are anticipated around 2028 when key US patents expire.
- Nivolumab biosimilars: BMS's exclusivity for Opdivo extends further than Keytruda's, with biosimilar entry expected after 2030 in the US.
- Interchangeability: The 2026 FDA streamlining of the interchangeability pathway (removing the requirement for switching studies in many cases) will accelerate biosimilar development for checkpoint inhibitors.
Access teams should begin formulary planning now: payer switching criteria, biosimilar-ready purchasing contracts, and physician communication about the coming transition.
Medicare Part B buy-and-bill economics
Checkpoint inhibitors are typically purchased by hospital outpatient departments and physician practices and reimbursed through Medicare Part B at ASP + 6%. Key considerations:
- Weight-based vs. flat dosing. Keytruda moved to a flat 400 mg Q6W dosing option in addition to the original weight-based 2 mg/kg Q3W regimen. Flat dosing simplifies inventory management and reduces waste.
- SC formulation cost differential. SC formulations carry higher per-dose WAC but may reduce overall administration costs (no infusion chair time, no IV supplies).
- Claims processing. Correct HCPCS coding is essential. Use of unclassified codes (J3590, J9999) for products with dedicated J-codes will delay reimbursement.
Market concentration
The PD-1/PD-L1 axis accounts for 115 of 155 oncology immune checkpoint inhibitor approvals worldwide — 74% of all ICI indications, according to the Cancer Research Institute's 2026 Cancer Immunotherapy Impact Report. This concentration reflects the clinical utility of checkpoint blockade but also highlights how narrowly the field has validated targets. The next generation of checkpoint targets (LAG-3, TIM-3, TIGIT) has produced only one approval (Opdualag's relatlimab component) in over a decade.
Keytruda alone holds an estimated 49.1% share of the global checkpoint inhibitor market in 2026, followed by Opdivo at 26.1%. The top three brands (Keytruda, Opdivo, Tecentriq) hold approximately 91% of global PD-(L)1 sales by value, creating a highly concentrated market that payers can manage through a small number of preferred products.
What to monitor next
| Signal | Timeline | Access impact |
|---|---|---|
| Keytruda/Opdivo IRA Part B MFP selection | 2027–2028 | Part B reimbursement rate reduction |
| First pembrolizumab biosimilar launch | ~2028 | ASP erosion, payer switching |
| Additional SC formulation approvals | 2026–2027 | Administration setting shift, billing changes |
| New indication expansions (adjuvant, neoadjuvant) | Ongoing | Patient volume growth, PA criteria updates |
| Payer step therapy consolidation | 2026 | Preferred product shifts, market share movement |
Sources
- FDA Novel Drug Approvals 2026. U.S. Food and Drug Administration. fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- Premera Blue Cross. Immune Checkpoint Inhibitors Medical Policy 5.01.591, effective July 2, 2026.
- UnitedHealthcare Medicare Advantage Medical Policy Update Bulletin, April 2026. Medicare Part B Step Therapy Programs.
- Aetna Medicare Part B Drug Step Criteria for PD-1/PD-L1 Inhibitors. Policy 1022-AMBST, effective March 2026.
- Highmark Medicare Advantage Medical Policy I-120-0467: Programmed Death Receptor (PD-1)/Programmed Death-Ligand (PD-L1) Blocking Antibodies, effective May 2026.
- OncoHealth. PD-1/PD-L1 Medical Policy. Revised October 2024.
- ASTCT. Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer? Evidence-Based Oncology (EBO), 2026.
- CMS. Drugs Likely Subject to Medicare Negotiation, 2026–2028. PMC/NIH.
- Keytruda (pembrolizumab) Prescribing Information. Merck & Co., Inc.
- Opdivo (nivolumab) Prescribing Information. Bristol-Myers Squibb.
- Tecentriq (atezolizumab) Prescribing Information. Genentech, Inc.
- Imfinzi (durvalumab) Prescribing Information. AstraZeneca Pharmaceuticals LP.
- Bavencio (avelumab) Prescribing Information. EMD Serono, Inc.
- Libtayo (cemiplimab) Prescribing Information. Regeneron Pharmaceuticals.
- Jemperli (dostarlimab) Prescribing Information. GlaxoSmithKline LLC.
